AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Alnylam’s AI Bets Point to a New RNAi Industrial Model
Alnylam is expanding its AI-driven drug discovery strategy through partnerships that could reshape how RNAi therapies are designed and developed. The move suggests RNAi is becoming a test bed for industrialized AI workflows, with potentially large financial stakes.
Inceptive and Alnylam’s $2 Billion Pact Shows RNAi Is Becoming an AI Playground
Alnylam’s collaboration with Inceptive is one of the biggest signals yet that AI foundation models are moving into RNAi therapeutics. The deal reflects a broader trend: drugmakers are increasingly willing to pair their domain expertise with AI firms that promise faster design and development cycles.
AI Helps Scientists Design Molecules That Target Specific Cells
Researchers report an AI-enabled method for designing molecules that selectively target particular cells, a step that could improve precision in therapeutics and reduce off-target effects. The work adds to a growing body of evidence that generative AI is becoming more useful when paired with specific biological constraints.
AI Is Making ‘Undruggable’ Disease Drivers a More Realistic Target
A profile of biotechnology veteran Pamela Carroll highlights how AI is being used to tackle disease drivers once considered undruggable. The broader message is that AI is helping researchers move from identifying difficult biology to creating practical ways to intervene in it.
Lung Cancer AI Is Shifting From Detection to Therapeutics
A GlobeNewswire release says AI disruption in lung cancer therapeutics is accelerating, pointing to a broader expansion beyond detection and triage. The significance is that AI is no longer being framed only as a diagnostic tool, but as part of the therapeutic strategy itself.
CADD and AI are converging on the next generation of therapeutics
A EurekAlert report frames computer-aided drug design and AI as increasingly inseparable in the search for next-generation therapeutics. The convergence suggests that the field is moving from standalone algorithms toward integrated design environments.
GLP-1 Drugs Are Expanding Beyond Obesity, and Neurology May Be the Next Real Test
Two reports this week spotlight the widening clinical conversation around GLP-1 medicines, including their potential role beyond weight loss and promising signals in chronic migraine. Together they show how one of medicine’s hottest drug classes is evolving into a broader platform story that could reshape care pathways well outside endocrinology.
Michigan State researchers argue AI can materially speed therapeutic discovery
Michigan State University researchers reported work suggesting AI can accelerate the search for therapeutic candidates. The significance is less about another speed claim and more about whether academic groups can demonstrate reproducible methods that industry can trust and build on.
New AI Model Highlights a Familiar Truth in Drug Discovery: Better Models Matter Only if Experiments Keep Up
A report on an AI model that accelerates therapeutic drug discovery points to ongoing technical progress in model-guided candidate generation and prioritization. But its broader significance is as a reminder that the field’s central bottleneck is increasingly the translation of computational gains into experimental throughput and validated biology.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.